WHC est encore en dévelopement. Lisez ceci pour comprendre notre approche.
depiction of GCKMFJBGXUYNAG-UHFFFAOYSA-N.svg
isomerdesign

Methyltestosterone

Vérifier sur isomerdesign

pubchem

Methyltestosterone

Vérifier sur pubchem

drugmap

Methyltestosterone

Vérifier sur drugmap

wiki

Methyltestosterone

Vérifier sur wiki

Data

InChI: InChI=1S/C20H30O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h12,15-17,22H,4-11H2,1-3H3

Synonymes: CDB 110,NCGC00091009-07,Testovis (tablet),DB06710,17(alpha)-methyl-Delta(4)-androsten-17(beta)-ol-3-one,METHYLTESTOSTERONE [WHO-DD],AB00443683-09,Testosterone, 17-methyl-,Premarin with Methyltestosterone (Salt/Mix),Oraviron,Methyltestosterone (JP17/USP/INN),Neo-Hombreol-M,Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17.beta.)-,METHYLTESTOSTERONE [USP-RS],METHYLTESTOSTERONE [WHO-IP],Methyltestosteronum,Androst-4-en-3-on-17.beta.-ol, 17.alpha.-methyl,DTXSID1033664,Homandren (VAN),Neo-Homobreol (M),CHEMBL1395,Metrone,DSSTox_RID_79089,17.alpha.-Methyl-3-oxo-4-androsten-17.beta.-ol,Methyltestosteronum [INN-Latin],Syndren,HSDB 3365,17beta-Hydroxy-17-methylandrost-4-en-3-one,17-MT,Glosso-sterandryl,NSC139965,17alpha-Methyltestosterone, VETRANAL(TM), analytical standard,Malogen,(17beta)-17-hydroxy-17-methylandrost-4-en-3-one,GTPL6945,NC00121,Androst-4-en-3-one, 17beta-hydroxy-17-methyl-,Testoviron (tablet),17.alpha.-methyl-.DELTA.4-androsten-17.beta.-ol-3-one,DSSTox_CID_13664,CHEBI:27436,CDB-110,Metestone,17-alpha-Methyltestosterone 100 microg/mL in Acetonitrile,Oretron,17α-Methyltestosterone,Synandrotabs,17(alpha)-Methyl-delta4-androsten-17(beta)-ol-3-one,17-alpha-Methyltestosterone,Masenone,(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one,C07198,Methyltestosterone for system suitability, European Pharmacopoeia (EP) Reference Standard,SMR000058528,GS-6594,METHYLTESTOSTERONE [INN],Metiltestosterone,METHYLTESTOSTERONE [USP MONOGRAPH],Hormale,HMS2272A06,(17-beta)-17-Hydroxy-17-methylandrost-4-en-3-one,NCGC00091009-04,Androsan (tablets),DSSTox_GSID_33664,Methyltestosterone, United States Pharmacopeia (USP) Reference Standard,HY-A0121,Estan (Salt/Mix),4-Androstene-17alpha-methyl-17beta-ol-3-one,Methyltestosterone aka ''(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one,Premarin with methyltestosterone,L 589.372,4-08-00-01010 (Beilstein Handbook Reference),NCGC00091009-03,Oreton-M,component of Gynetone,Metiltestosterona,ZINC3814422,Nabolin,METHYLTESTOSTERONE [HSDB],CS-5099,Malestrone,METHYL TESTOSTERONE,Metandren,NSC 139965,METHYLTESTOSTERONE [VANDF],Methyltestosterone (17alpha-Methyltestosterone) 1.0 mg/ml in Acetonitrile,LMST02020029,Q421768,Tox21_113162,component of Estan,17alpha-Methyltestosterone solution, 1.0 mg/mL in 1,2-dimethoxyethane, ampule of 1 mL, certified reference material,BDBM50410531,L-589372,4-Androstene-17-alpha-methyl-17-beta-ol-3-one,Anertan (VAN),17-.beta.-Hydroxy-17-methylandrost-4-en-3-one,M.T.Mucorettes,4-Androstene-17.alpha.-methyl-17.beta.-ol-3-one,17-Hydroxy-17-methyl-3-keto-androstene-4,Testhormone,17-Hydroxy-17-methylandrost-4-en-3-one #,Homandren,MLS001424040,(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one,Androst-4-en-3-one, 17.beta.-hydroxy-17-methyl-,.ALPHA.-METHYLTESTOSTERONE,Virilon,RU-24400,BRN 2057425,RU 24400,17alpha-methyl-Delta(4)-androsten-17beta-ol-3-one,EINECS 200-366-3,METHYLTESTOSTERONE [ORANGE BOOK],Metiltestosterona [INN-Spanish],Andrometh,Anertan, tablets,17alpha-methyl-Delta4-androsten-17beta-ol-3-one,17alpha-Methyltestosterone, solid (photosensitive),CAS-58-18-4,Estratest,AKOS015917317,Androsan (VAN),MLS002174282,17.alpha.-Methyltestosterone,NCGC00091009-01,OXANDROLONE IMPURITY, METHYLTESTOSTERONE- [USP IMPURITY],METHYLTESTOSTERONE [EP MONOGRAPH],Android 10,58-18-4,17alpha-Methyltestosterone, >=97.0% (HPLC),Androsan, tablets,D00408,Oxandrolone impurity, methyltestosterone-,MLS000759474,17-Methyltestosteron,17-METHYLTESTOSTERONE [MI],Glosso sterandryl,Mesterone,NSC-9701,Methitest,(1S,2R,10R,11S,14S,15S)-14-hydroxy-2,14,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one,Androst-4-ene-17.alpha.-methyl-17.beta.-ol-3-one,17alpha-Methyl-3-oxo-4-androsten-17beta-ol,L-589.372,SMR001261452,U 2842,17a-methyltestosterone,Methyltestosterone, European Pharmacopoeia (EP) Reference Standard,17-beta-Hydroxy-17-methylandrost-4-en-3-one,UNII-V9EFU16ZIF,Homandren, tablets,Neo-Hombreol [M],METHYLTESTOSTERONUM [WHO-IP LATIN],Testora,component of Gynetone (Salt/Mix),METHYLTESTOSTERONE [MART.],17alpha-Methyltestosterone,17-Methyltestosterone,Dumogran,HMS2051A14,CCG-100871,Android 5,NSC-139965,Testred,Estratest (Salt/Mix),NSC9701,Androst-4-en-3-one, 17-hydroxy-17-methyl-, (17b)-,AB00443683-06,component of Tylosterone,Steronyl,17|A-Methyltestosterone,U-2842,V9EFU16ZIF,Androsan,Anertan,17.beta.-Hydroxy-17.alpha.-methylandrost-4-en-3-one,Testred (TN),Android (TN),17alpha-Methyl-delta-androsten-17beta-ol-3-one,NCGC00091009-05,METHYLTESTOSTERONE [JAN],(8R,10R,13S,17S)-17-Hydroxy-10,13,17-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one,Neo-Homobreol [M],Mastestona,Orchisterone-M,Testovis Depot,Androst-4-en-3-one, 17-beta-hydroxy-17-methyl-,Methyltestosterone,NCGC00091009-06,Anertan (tablets),Oreton M,Tox21_400058,Tox21_113162_1,WLN: L E5 B666 OV MUTJ A E FQ F -B&AEF,Nu-man,SCHEMBL18657,Tox21_113161,Metiltestosterone [DCIT],Methyltestosterone [USP:INN:BAN:JAN],Methyltestosterone (17alpha-Methyltestosterone),CCRIS 3723,Android,Methyltestosterone ciii,Oreton Methyl,Testoviron (VAN),methyltestosterone,Android 25,M0435,Androsten,Synandrets


Estimated data

Solubility: -4.543 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 72.9% (prediction based on www.mdpi.com)

Similitudes

Voici une série de comparaisons visant à comprendre les propriétés de ce composé. Ce site est encore très expérimental et fait l'objet d'un développement actif. Veuillez vous référer à notre série d'articles d'articles pour bien comprendre notre approche et ses limites. Ces informations sont données à titre indicatif et ne doivent pas être interprétées comme des conseils médicaux.